Monitor Dr. Reddy's Q1 FY27 earnings (due in ~2 weeks) for inventory write-down details and updated semaglutide revenue guidance. Track progress on root-cause analysis and re-validation timelines; any extension beyond September would further pressure the stock. Competitors like Sandoz and Aspen may accelerate their own GLP-1 launches, increasing competitive risk.
Price Chart
Executive Summary
Dr. Reddy's disclosed a manufacturing impurity issue in the scale-up of its semaglutide injection API, causing a halt in commercial supply for approximately three months. The company now expects to supply only 6-7 million pens in FY27 (down from prior guidance of ~12 million), with no patient safety impact or recall. This is a material negative for near-term revenue from its key GLP-1 product.
Key Facts
- Impurity (degradation) detected in finished drug product from a scale-up validation batch of semaglutide injection API.
- Commercial supply halted until process is fixed and re-validated; expected resumption late October/early November 2026.
- FY27 semaglutide pen guidance revised to 6-7 million pens (from prior ~12 million), with supply concentrated in Q3-Q4.
- No patient safety impact, no recall of previously supplied product, and no impact on oral semaglutide or existing regulatory filings.
- Potential write-down of inventory held at partner OneSource; no penalty clauses in partner agreements but down payments may be renegotiated.
Financial Impact
FY27 semaglutide injection revenue cut by roughly 40-50% vs prior expectations; potential inventory write-down of undisclosed amount; no penalty fees but possible renegotiation of customer advances.
Risk Factors
- Further delay if re-validation fails again, pushing commercial supply into 2027.
- Loss of market share to competitors (Sandoz, Aspen, Torrent) during the supply gap.
- Potential partner renegotiations or termination if supply reliability is questioned.
- Regulatory scrutiny if impurity issue escalates, though no agency notification required currently.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000504 |
| Document: 0001575872-26-000504-index.html | 0001575872-26-000504 |
| Document: 0001575872-26-000504.txt | 0001575872-26-000504 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $11.91 $11.55 | ▼ −3.02% | ▼ −2.56% | $12.25 (+2.85%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Aug 26, 2026 5w ago | 6-K | $12.22 $12.16 | ▼ −0.49% | ▼ −1.15% | $12.25 (+0.25%) |
Aug 17, 2026 6w ago | 6-K | $12.11 $12.15 | ▲ +0.33% | ▲ +1.01% | $12.25 (+1.16%) |
Aug 13, 2026 7w ago | 6-K | $12.42 $12.27 | ▼ −1.21% | ▼ −1.01% | $12.25 (−1.37%) |
Aug 10, 2026 7w ago | 6-K | $12.15 $12.45 | ▲ +2.47% | ▲ +2.79% | $12.25 (+0.82%) |
Aug 3, 2026 8w ago | 6-K | $12.07 $12.10 | ▲ +0.25% | ▼ −1.55% | $12.25 (+1.49%) |
Jul 29, 2026 9w ago | 6-K | $11.76 $11.83 | ▲ +0.60% | ▼ −1.08% | $12.25 (+4.17%) |
Jul 23, 2026 10w ago | 6-K | $11.80 $11.79 | ▼ −0.08% | ▼ −0.19% | $12.25 (+3.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access